---
title: "UCBJY.US (UCBJY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/UCBJY.US/news.md"
symbol: "UCBJY.US"
name: "UCBJY.US"
parent: "https://longbridge.com/en/quote/UCBJY.US.md"
datetime: "2026-05-20T00:16:13.811Z"
locales:
  - [en](https://longbridge.com/en/quote/UCBJY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UCBJY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UCBJY.US/news.md)
---

# UCBJY.US (UCBJY.US) — Related News

### [Bimzelx head-to-head Phase III study successful, with significant improvement in plaque psoriasis arthritis indicators compared to Skyrizi](https://longbridge.com/en/news/286936685.md)
*2026-05-19T15:05:39.000Z*
> Belgian biopharmaceutical company UCB announced the results of the Phase III BE BOLD study for the IL-17A/IL-17F inhibit

### [UCB reports positive outcomes for bimekizumab in psoriatic arthritis](https://longbridge.com/en/news/286906544.md)
*2026-05-19T11:48:33.000Z*
> UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating

### [FOMO2026: The major changes in global innovative drugs, not many people understand it yet](https://longbridge.com/en/news/286487435.md)
*2026-05-15T00:49:46.000Z*
> In 2026, Bayer acquired Perfuse Therapeutics for a maximum of $2.45 billion, UCB acquired Candid Therapeutics for $2 bil

### [UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies](https://longbridge.com/en/news/285531097.md)
*2026-05-07T10:35:55.000Z*
> UCB has formed a multi-project strategic alliance with Cancer Research UK and Cancer Research Horizons to enhance the de

### [Qiming Venture Partners' Chen Kan: China's Biotech can achieve excess returns through different methods](https://longbridge.com/en/news/285587767.md)
*2026-05-07T10:17:41.000Z*
> Dr. Chen Kan, a partner at Qiming Venture Partners, stated that the Chinese biotechnology industry can achieve excess re

### [UCB doubles down on TCEs with $2.2bn Candid buyout](https://longbridge.com/en/news/285196071.md)
*2026-05-05T10:12:54.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)](https://longbridge.com/en/news/285164304.md)
*2026-05-05T06:16:01.000Z*
> In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA, with a price target of €

### [EDDING GENOR's partner CT has been acquired by the Belgian pharmaceutical group UCB, expected to be completed by the end of the second quarter at the earliest](https://longbridge.com/en/news/285137972.md)
*2026-05-05T00:40:00.000Z*
> EDDING GENOR announced progress in its collaboration with Candid Therapeutics (CT), which has been acquired by the Belgi

### [EDDING GENOR: Candid Therapeutics was acquired by UCB with an initial payment of $2 billion](https://longbridge.com/en/news/285089679.md)
*2026-05-04T14:57:03.000Z*
> EDDING GENOR announced that it has signed a licensing agreement and equity agreement with TRC 2004, Inc. to acquire equi

### [<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>](https://longbridge.com/en/news/285081451.md)
*2026-05-04T13:16:01.000Z*
> UCB has agreed to acquire Candid Therapeutics for over $2.2 billion, which includes the clinical-stage T-cell engager ci